ArticleJournal of clinical microbiology2023
Terbinafine-Resistant Dermatophytes and the Presence of Trichophyton indotineae in North America.
Article in Journal of clinical microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 3 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Pooled it
- Emerging Terbinafine Resistant Trichophyton Dermatophytosis, Testing Options and Alternative Treatments: A Systematic Review.The Australasian journal of dermatology · 2025Pooled it
- Mapping the Global Spread of T. indotineae: An Update on Antifungal Resistance, Mutations, and Strategies for Effective Management.Mycopathologia · 2024Pooled it
- Article
- Microsporum canis complex infections in the United Arab Emirates: Clinical, molecular, and antifungal susceptibility profiles.Medical mycology · 2026Article
- Emergence ofJAC-antimicrobial resistance · 2026Article
- Emerging Global Patterns of Terbinafine Resistance inAntibiotics (Basel, Switzerland) · 2026Review
- Dermatophytosis: An Update on Global Epidemiology.Journal of fungi (Basel, Switzerland) · 2026Review
- Trichophyton indotineae: Rise, Diagnosis, Treatment, and Future Directions.American journal of clinical dermatology · 2026Review
- Fungicidal Activity of the Nitroimidazole-Thiosemicarbazide Derivative 1-[(1-methyl-4-nitroimidazol-2-yl)carbonyl]-4-(3-methylophenyl)thiosemicarbazide AgainstPathogens (Basel, Switzerland) · 2026Article
- Resistance and Recalcitrance in Dermatophytosis: Mechanistic and Clinical Considerations for Keratinized Tissues.Antibiotics (Basel, Switzerland) · 2026Review
- Disruption of thePathogens (Basel, Switzerland) · 2026Article
- Article
- The emergence of superficial dermatophytosis due toJournal of clinical microbiology · 2026Article
- A Study on the Species Diversity, Mating Types, and Clinical Relevance of Trichophyton mentagrophytes/interdigitale Complex Infections in Guizhou Province.Mycopathologia · 2026Article
- Establishment of epidemiological cutoff values for clinically relevantAntimicrobial agents and chemotherapy · 2026Article
- Article
- The dual role of azoles: lifesaving antifungals and drivers of resistance - a One Health perspective.Nature communications · 2026Review
- Molecular Characterization and Preliminary NGS Profiling of Terbinafine-ResistantPathogens (Basel, Switzerland) · 2026Article
- New and Investigational Treatment Options for Dermatomycosis in the Era of Antifungal Resistance.Journal of fungi (Basel, Switzerland) · 2026Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatophytes are common causes of skin, hair, and nail infections in humans. The most common species causing infections in humans are Trichophyton rubrum, Trichophyton mentagrophytes, and Trichophyton interdigitale. Outbreaks of recalcitrant dermatophytosis have been reported in parts of South Asia, including those caused by a hypervirulent and resistant species, Trichophyton indotineae. We evaluated the antifungal susceptibility profiles of dermatophytes received by our laboratory from institutions across North America between 2021 and 2022 and performed species identification for isolates deemed to demonstrate
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.